Evidence map›Paper›PMID 20026215›Full record

ArticleJournal of structural biology2010

Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant Staphylococcus aureus dihydrofolate reductase.

Kathleen M Frey, Michael N Lombardo, Dennis L Wright, Amy C Anderson

Abstract read
In one paragraph

Article in Journal of structural biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 47 citations in OpenAlex.

  1. Molecular Basis of Non-β-Lactam Antibiotics Resistance inAntibiotics (Basel, Switzerland) · 2022
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Protein design algorithms predict viable resistance to an experimental antifolate.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Acetylenic linkers in lead compounds: a study of the stability of the propargyl-linked antifolates.Drug metabolism and disposition: the biological fate of chemicals · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kathleen M FreyDepartment of Pharmaceutical Sciences, University of Connecticut, 69 N. Eagleville Rd., Storrs, CT 06269, USA.
Michael N Lombardo
Dennis L Wright
Amy C Anderson
University of Connecticut · US

Funding

Case Center for Synchrotron BiosciencesP30EB009998 · NIBIB · CASE WESTERN RESERVE UNIVERSITY · PI CHANCE, MARK R · 2009 to 2018
$8.4M
Targeting DHFR to Design Antimicrobial AgentsR01GM067542 · NIGMS · UNIVERSITY OF CONNECTICUT STORRS · PI ANDERSON, AMY C. · 2003 to 2012
$2.2M
Targeting Bacillus DHFR: Structural Studies and Synthesis of InhibitorsR01AI073375 · NIAID · UNIVERSITY OF CONNECTICUT STORRS · PI ANDERSON, AMY C. · 2008 to 2012
$1.7M
Potent Antifolates as New Therapeutics for MRSAR42AI065143 · NIAID · PROMILIAD BIOPHARMA, INC. · PI WRIGHT, DENNIS L. · 2010 to 2011
$1.5M
Potent and selective DHFR inhibitors for treating CryptosporidiosisR41AI065143 · NIAID · PROMILIAD BIOPHARMA, INC. · PI WRIGHT, DENNIS L · 2006 to 2006
$279k
NIAID NIH HHS AI065143NIAID NIH HHS AI073375NIAID NIH HHS R01 AI073375NIAID NIH HHS R41 AI065143NIAID NIH HHS R42 AI065143NIBIB NIH HHS P30 EB009998NIGMS NIH HHS GM067542NIGMS NIH HHS R01 GM067542
6 · The paper itself

Abstract

Resistance to therapeutics such as trimethoprim-sulfamethoxazole has become an increasing problem in strains of methicillin-resistant Staphylococcus aureus (MRSA). Clinically isolated trimethoprim-resistant strains reveal a double mutation, H30N/F98Y, in dihydrofolate reductase (DHFR). In order to develop novel and effective therapeutics against these resistant strains, we evaluated a series of propargyl-linked antifolate lead compounds for inhibition of the mutant enzyme. For the propargyl-linked antifolates, the F98Y mutation generates minimal (between 1.2- and 6-fold) losses of affinity and the H30N mutation generates greater losses (between 2.4- and 48-fold). Conversely, trimethoprim affinity is largely diminished by the F98Y mutation (36-fold) and is not affected by the H30N mutation. In order to elucidate a mechanism of resistance, we determined a crystal structure of a complex of this double mutant with a lead propargyl-linked antifolate. This structure suggests a resistance mechanism consistent both for the propargyl-linked class of antifolates and for trimethoprim that is based on the loss of a conserved water-mediated hydrogen bond.

Indexed as

Models, MolecularCloning, MolecularCrystallizationFolic Acid AntagonistsMethicillin ResistanceMolecular StructureMutation, MissenseStaphylococcus aureusTetrahydrofolate DehydrogenaseTrimethoprimTrimethoprim ResistanceFolic Acid AntagonistsTetrahydrofolate DehydrogenaseTrimethoprimantifolatesdihydrofolate reductasemethicillin-resistant Staphylococcus aureustrimethoprim

Identifiers

PMID20026215
PMCPMC2841211
OpenAlexW1994670783

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.